imatinib mesylate has been researched along with Histiocytoma, Benign Fibrous in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Buljan, M; Crnarić, I; Delaš Aždajić, M; Šitum, M; Vučić, M | 1 |
| Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Solano-López, GE; Steegmann, JL | 1 |
| Ambrifi, M; Bottoni, U; Calvieri, S; Clerico, R; Corsetti, P; Didona, D; Paolino, G | 1 |
3 other study(ies) available for imatinib mesylate and Histiocytoma, Benign Fibrous
| Article | Year |
|---|---|
From Morphea to Dermatofibrosarcoma Protuberans.
Topics: Adult; Cicatrix; Dermatofibrosarcoma; Disease Progression; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Scleroderma, Localized; Skin Neoplasms; Young Adult | 2022 |
Multiple eruptive dermatofibromas related to imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Female; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Skin; Treatment Outcome | 2014 |
Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dermatitis, Seborrheic; Dermatomycoses; Drug Eruptions; Eczema; Edema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Keratosis, Actinic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Orbital Diseases; Prospective Studies; Pruritus; Psoriasis; Skin Neoplasms | 2016 |